Overview

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Bimatoprost